Who Paid My Doc
Edgar Domenech Fagundo
Plastic Surgery within the Head & Neck Ponce, PR Medical Doctor
NPI 1386717247 CMS profile 573201
909 Ave Tito Castro, Suite 618 Torre Medica San Lucas, Ponce, PR 00716
General payments
$1,907
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Edgar Domenech Fagundo of Ponce, PR is reported in the CMS Open Payments database as having received $1,907 across 41 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 64th percentile of Plastic Surgery within the Head & Neck profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $615 | 12 | |
| 2024 | General | $156 | 4 | |
| 2023 | General | $204 | 4 | |
| 2022 | General | $428 | 8 | |
| 2021 | General | $198 | 4 | |
| 2020 | General | $107 | 5 | |
| 2019 | General | $200 | 4 |
Beside peers
- Edgar Domenech Fagundo
- Plastic Surgery within the Head & Neck median
- Middle half of Plastic Surgery within the Head & Neck
- National median
In program year 2025, general payments to Edgar Domenech Fagundo were reported at $615. Among 399 Plastic Surgery within the Head & Neck profiles paid that year, the median was $237 and the middle half received between $103 and $520.
Show as a table
| Year | Edgar Domenech Fagundo | Plastic Surgery within the Head & Neck median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $200 | $200 | $82–$550 | $163 |
| 2020 | $107 | $120 | $46–$330 | $114 |
| 2021 | $198 | $166 | $60–$382 | $132 |
| 2022 | $428 | $208 | $83–$530 | $149 |
| 2023 | $204 | $202 | $77–$538 | $160 |
| 2024 | $156 | $260 | $99–$645 | $164 |
| 2025 | $615 | $237 | $103–$520 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 23 drugsPart D claims
1,010
Drug cost
$39,382
Branded share of claims
28%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Fluocinolone Acetonide Oil | Generic | 120 | $9,109 | |
| Azelastine-Fluticasone Azelastine/Fluticasone | Brand | 82 | $7,745 | |
| Neomycin-Polymyxin-Hc Neomycin/Polymyxin B/Hydrocort | Brand | 67 | $4,735 | |
| Synthroid Levothyroxine Sodium | Brand | 59 | $3,431 | |
| Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth | Brand | 15 | $2,253 | |
| Lansoprazole | Generic | 140 | $2,063 | |
| Neomycin-Polymyxin-Hydrocort Neomycin/Polymyxin B/Hydrocort | Brand | 29 | $1,963 | |
| Fluticasone Propionate | Generic | 80 | $1,587 | |
| Hydrocortisone-Acetic Acid Hydrocortisone/Acetic Acid | Brand | 11 | $1,465 | |
| Azelastine Hcl | Generic | 52 | $1,256 |
The 10 drugs with the highest cost, of 23 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 11 billing codesPaid by Medicare
$9,757
Medicare patients
66
Services billed
159
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 61% | |
| Arthritis | 39% | |
| Chronic kidney disease | 36% | |
| Osteoporosis | 30% | |
| Ischemic heart disease | 26% | |
| Alzheimer's or dementia | 18% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
41 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Plastic Surgery within the Head & Neck in Puerto Rico
Gabriel Pujol Cuevas
Plastic Surgery within the Head & Neck · Ponce, PR
Jose Sanchez Mendiola
Plastic Surgery within the Head & Neck · Carolina, PR
Pablo Lopez Baez
Plastic Surgery within the Head & Neck · Bayamon, PR
Jose Sanchez Perez
Plastic Surgery within the Head & Neck · Bayamon, PR
Luis Valledor Maeso
Plastic Surgery within the Head & Neck · Hato Rey, PR
Francis Beauchamp-Perez
Plastic Surgery within the Head & Neck · San Juan, PR
Related records
Plastic Surgery within the Head & Neck in Puerto Rico
Practitioners in the same specialty and state, ranked by reported value.
All Plastic Surgery within the Head & Neck
Everyone recorded under this specialty, nationwide.
Doctors in Puerto Rico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.